Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders (MAN-BIOPSY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01477203|
Recruitment Status : Completed
First Posted : November 22, 2011
Last Update Posted : September 14, 2016
MAN-BIOPSY pursues the concrete research question whether novel biological and psycho-physiological clusters or categories can be defined to improve treatment and minimize side effects in psychiatry, based on a synopsis of physiological, behavioural, genetic and endocrinological parameters. One major aspect of our research approach is its focuses on the identification of dysfunctions in fundamental information processing mechanisms and neurocomputational mechanisms, and is not restricted to symptom-oriented tasks.
The main objectives of MAN-BIOPSY are therefore
- to identify biological and psycho-physiological parameters for major depressive disorders and anxiety disorders, and
- to identify predictive markers for treatment response and type/severity of side effects for these disorders.
|Condition or disease||Intervention/treatment||Phase|
|Major Depressive Disorder (MDD) Anxiety Disorder||Drug: Escitalopram||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||289 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders|
|Study Start Date :||November 2011|
|Actual Primary Completion Date :||September 2016|
|Actual Study Completion Date :||September 2016|
Active Comparator: Escitalopram
50 Major Depressive Disorder Patients and 50 Anxiety Disorder Patients will receive Escitalopram as medication
2-4 weeks, 5-10mg, max 20mg
|No Intervention: Remitted Patients|
|No Intervention: Healthy Controls|
- SSRI induced changes in BOLD (blood oxygen level dependent) response over time [ Time Frame: 4 vears ]
- SSRI induced changes in ERPs (event-related potentials) over time [ Time Frame: 4 years ]
- biochemical data [ Time Frame: 4 years ]these include steroid hormone levels, vitamins, etc.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01477203
|Medical University of Vienna, Department for Psychiatrie and Psychotherapie|
|Vienna, Austria, 1090|